Volume | 71,412 |
|
|||||
News | - | ||||||
Day High | 1.80 | Low High |
|||||
Day Low | 1.30 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Protagenic Therapeutics Inc | PTIX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.30 | 1.30 | 1.80 | 1.57 | 1.25 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
338 | 71,412 | $ 1.50 | $ 107,323 | - | 0.6797 - 2.32 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:20:28 | 10 | $ 1.50 | USD |
Protagenic Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
6.96M | 4.44M | - | 0 | -5M | -1.13 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Protagenic Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PTIX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.40 | 1.80 | 1.1535 | 1.31 | 4,229 | 0.17 | 12.14% |
1 Month | 1.67 | 1.87 | 1.1535 | 1.64 | 9,097 | -0.10 | -5.99% |
3 Months | 0.823 | 1.87 | 0.77 | 1.29 | 10,942 | 0.747 | 90.77% |
6 Months | 0.85 | 1.87 | 0.6797 | 1.11 | 8,566 | 0.72 | 84.71% |
1 Year | 1.73 | 2.32 | 0.6797 | 1.28 | 8,647 | -0.16 | -9.25% |
3 Years | 11.00 | 19.56 | 0.6797 | 11.27 | 445,285 | -9.43 | -85.73% |
5 Years | 11.00 | 19.56 | 0.6797 | 11.27 | 445,285 | -9.43 | -85.73% |
Protagenic Therapeutics Description
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders. |